Stock Scorecard
Stock Summary for Lyell Immunopharma Inc (LYEL) - $11.61 as of 6/29/2026 11:36:44 AM EST
Total Score
10 out of 30
Safety Score
32 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for LYEL
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for LYEL
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for LYEL
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for LYEL
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for LYEL (32 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 6 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for LYEL
Financial Details for LYEL
Company Overview |
|
|---|---|
| Ticker | LYEL |
| Company Name | Lyell Immunopharma Inc |
| Country | N/A |
| Description | Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 3/31/2026 |
| Next Earnings Date | 8/11/2026 |
Stock Price History |
|
| Last Day Price | 11.61 |
| Price 4 Years Ago | 69.40 |
| Last Day Price Updated | 6/29/2026 11:36:44 AM EST |
| Last Day Volume | 1,698,427 |
| Average Daily Volume | 182,181 |
| 52-Week High | 45.00 |
| 52-Week Low | 8.46 |
| Last Price to 52 Week Low | 37.23% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 110.31 |
| Sector PE | 77.87 |
| 5-Year Average PE | -6.54 |
| Free Cash Flow Ratio | 2.98 |
| Industry Free Cash Flow Ratio | 19.76 |
| Sector Free Cash Flow Ratio | 34.98 |
| Current Ratio Most Recent Quarter | 7.23 |
| Total Cash Per Share | 3.89 |
| Book Value Per Share Most Recent Quarter | 11.73 |
| Price to Book Ratio | 1.11 |
| Industry Price to Book Ratio | 13.76 |
| Sector Price to Book Ratio | 12.80 |
| Price to Sales Ratio Twelve Trailing Months | 9,947.47 |
| Industry Price to Sales Ratio Twelve Trailing Months | 6.20 |
| Sector Price to Sales Ratio Twelve Trailing Months | 32.76 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 23,334,100 |
| Market Capitalization | 270,908,901 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 19.98% |
| Reported EPS 12 Trailing Months | -13.62 |
| Reported EPS Past Year | -1.10 |
| Reported EPS Prior Year | -16.30 |
| Net Income Twelve Trailing Months | -246,406,000 |
| Net Income Past Year | -274,448,000 |
| Net Income Prior Year | -342,994,000 |
| Quarterly Revenue Growth YOY | -71.40% |
| 5-Year Revenue Growth | -65.85% |
| Operating Margin Twelve Trailing Months | -2,213,050.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 90,770,000 |
| Total Cash Past Year | 60,181,000 |
| Total Cash Prior Year | 105,597,000 |
| Net Cash Position Most Recent Quarter | 90,770,000 |
| Net Cash Position Past Year | 60,181,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 248,202,000 |
| Total Stockholder Equity Prior Year | 382,824,000 |
| Total Stockholder Equity Most Recent Quarter | 273,665,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -134,419,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -5.76 |
| Free Cash Flow Past Year | -150,804,000 |
| Free Cash Flow Prior Year | -162,858,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 15.01 |
| 20-Day Bollinger Middle Band | 21.08 |
| 20-Day Bollinger Upper Band | 27.16 |
| Beta | -0.09 |
| RSI | 23.32 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 6/27/2026 3:20:18 AM EST |